ClinicalTrials.gg
RecruitingNCT05916755PORTRAITUpdated Jun 23, 2023

Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform

An observational study in Triple Negative Breast Cancer, sponsored by Vall d'Hebron Institute of Oncology. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-23.

Sponsored by Vall d'Hebron Institute of Oncology · Observational

How we know · 4 judgments

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 136 studies in Triple Negative Breast Neoplasms with a site in Spain — 24 open to participants now, 48 under way, 10 of them phase 3. Triple Negative Breast Neoplasms · Spain.

Started
2023
with 6 others
Observational
2 of 136
2 open now
Primary completion
2026-12
later than 7 of 47 live
Registered
112th of 136
by date

Among the 136 studies in Triple Negative Breast Neoplasms with a site in Spain, this one is one of 7 that started in 2023, is one of 2 observational ones, reaches primary completion later than 7 of the 47 other live ones, and was the 112th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

24 of the 136 studies in Triple Negative Breast Neoplasms with a site in Spain are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 136 studies in Triple Negative Breast Neoplasms with a site in Spain, or all of them as a file.
02

Study summary

Patients with stage II-III Triple negative breast cancer (TNBC) candidates to receive neoadjuvant chemotherapy (NACT) +/- immune checkpoint inhibitor (ICI) will be included. Several samples from different tissues will be analyzed through different omics to establish predictive biomarkers of response to the treatment. Multiple algorithms will then be used to look for an integrative predictive algorithm that incorporates multi-parameter inputs in order to develop a clinical tool to assist clinicians in the process of treatment decision-making in TNBC.

Read the detailed description

The combination of pembrolizumab, an immune checkpoint inhibitor (ICI), with neoadjuvant chemotherapy (NACT) increases pathologic complete response (pCR) and event-free survival (EFS) in patients with early triple negative breast cancer (eTNBC). However, not all patients equally benefit from a treatment that may have relevant adverse events (AEs).

Objectives: (1) To establish predictive biomarkers of response to NACT + ICI in eTNBC by correlating data coming from different layers of omics performed in different tissues, together with imaging, with pCR, EFS, and overall survival (OS). (2) To integrate data generated from (1), and clinical data, and explore multivariate predictive models of response to NACT + ICI.

Methods: Patients with stage II-III TNBC candidates to receive NACT +/- ICI will be included. Collected samples and type of analysis: (1) Tumor tissue (baseline and from residual disease after NACT): whole genome sequencing (WGS) and RNA-Seq will be performed (Hartwig sequencing platform and analytical pipeline), tissue immune phenotyping (PD-L1, T and B infiltrating lymphocytes, among others), and microbiome analysis (16S rRNA); (2) Blood (before and during NACT): circulating tumor DNA (ctDNA) analysis (targeted gene panel and shallow WGS), T-cell receptor beta (TCR-β) repertoire sequencing and analysis (ImmunoSeq hsTCRβ kit and immunoSEQ), and peripheral blood mononuclear cells (PBMCs) phenotyping; (3) Stools and saliva (before and during NACT): microbiome analysis (16S rRNA); (4) Breast MRI imaging (before and after NACT): radiomics analysis. Multiple algorithms including Multiple Kernel Learning, Multi-Omics Factor Analysis (MOFA) and Method for the Functional Integration of Spatial and Temporal Omics data (MEFISTO) will then be used to look for an integrative predictive algorithm that incorporates multi-parameter inputs. The aim is to provide more personalized treatment efficacy and risk for relapse estimates.

Expected outcome: To develop a clinical tool to assist clinicians in the process of treatment decision-making in eTNBC, in order to maximize patient's benefit and quality of life, while minimizing AEs and financial burden to the health system.

03

Conditions studied

  • Triple Negative Breast Cancer

Keywords

  • Circulating biomarkers
  • clinical tool
  • immune checkpoint inhibitors
  • integrative algorithm
  • microbiome
  • multiomics
  • neoadjuvant chemotherapy
  • predictive biomarkers
  • radiomics
  • RNA-Sequencing
  • triple negative breast cancer
  • WGS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with stage II-III TNBC candidates to receive NACT +/- ICI will be included

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • documented TNBC (negative human epidermal growth factor receptor 2 [], estrogen receptor [ER], and progesterone receptor [PgR] status)
  • Stage 2 - 3 defined by the American Joint Committee of Cancer (AJCC) staging criteria 8th edition for breast cancer as assessed by the investigator based on radiological and/or clinical assessment
  • Patient is a candidate to receive NACT with or without ICI as assessed by the investigator
  • Patient is ≥ 18 years old at the time of consent to participate in this trial

Exclusion criteria

Exclusion Criteria:

  • disease on imaging (stage 4)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Cohort A

    Pembrolizumab + neoadjuvant chemotherapy

    Diagnostic Test: Whole Genome Sequencing · Diagnostic Test: RNA-Sequencing · Diagnostic Test: Microbiome analysis · Diagnostic Test: ctDNA analysis · Diagnostic Test: TCR-β repertoire sequencing · Diagnostic Test: PBMCs phenotyping · Drug: Pembrolizumab · Drug: Chemotherapy

  • Cohort B

    Neoadjuvant chemotherapy

    Diagnostic Test: Whole Genome Sequencing · Diagnostic Test: RNA-Sequencing · Diagnostic Test: Microbiome analysis · Diagnostic Test: ctDNA analysis · Diagnostic Test: TCR-β repertoire sequencing · Diagnostic Test: PBMCs phenotyping · Drug: Chemotherapy

Interventions

  • Diagnostic testWhole Genome Sequencing

    Whole genome sequencing (WGS) will be performed in tumor tissue from baseline and from residual disease after neoadjuvant chemotherapy (NACT), if present.

    Also known as: WGS

  • Diagnostic testRNA-Sequencing

    RNA-Sequencing will be performed in tumor tissue from baseline and from residual disease after NACT (if present).

  • Diagnostic testMicrobiome analysis

    Microbiome analysis will be performed in stools and saliva before, during NACT and at the end of adjuvant systemic therapy if adjuvant systemic therapy is clinically indicated.

  • Diagnostic testctDNA analysis

    ctDNA analysis will be performed in plasma before and during NACT.

  • Diagnostic testTCR-β repertoire sequencing

    TCR-β repertoire sequencing will be performed in plasma before and during NACT.

  • Diagnostic testPBMCs phenotyping

    PBMCs phenotyping will be performed in plasma before and during NACT.

  • Pembrolizumab will be given in combination with standard NACT.

  • DrugChemotherapy

    Standard NACT will be given.

    Also known as: Carboplatin, taxane, anthracycline, cyclophosphamide

06

What researchers measure

Primary outcomes

  1. Pathologic complete response (pCR) rate at definitive surgery

    The rate (given as a percentage) of patients with a pCR at definitive surgery using the definition of ypT0/Tis ypN0 (i.e., no invasive residual in breast or nodes; noninvasive breast residuals allowed) from the American Joint Committee on Cancer (AJCC) staging criteria

    Time frame: after neoadjuvant treatment and surgery, up to approximately 27-30 weeks

  2. Event-free survival (EFS)

    EFS is defined as the time from the start of neoadjuvant treatment to any of the following events: progression of disease that precludes surgery, local or distant recurrence, second primary malignancy (breast or other cancers) or death due to any cause

    Time frame: Up to approximately 60 months

  3. Overall survival (OS)

    OS is defined as the time from starting neoadjuvant treatment until death due to any cause

    Time frame: Up to approximately 60 months

  4. Identification of biomarkers to predict clinical outcomes (pCR at definitive surgery, EFS, OS).

    The clinical data (pCR at definitive surgery, EFS, OS) will be integrated with the results from the multiomics platform and multivariate predictive models of response to neoadjuvant chemotherapy (NACT) + immune checkpoint inhibitor (ICI) will be explored. Precisely, the multiomics platform will analyze: 1. RNA-Sequencing of the initial tumor and residual disease (if present) 2. microbiome analysis of the saliva and feces, 3. circulating tumor DNA (ctDNA) analysis (targeted gene panel and shallow WGS), 4. Tissue immune phenotyping, 5. T-cell receptor beta (TCR-β) repertoire sequencing and analysis using ImmunoSeq hsTCRβ kit and immunoSEQ, 6. Breast MRI imaging (before and after NACT), Multiple algorithms including Multiple Kernel Learning, Multi-Omics Factor Analysis (MOFA) and Method for the Functional Integration of Spatial and Temporal Omics data (MEFISTO) will then be used to look for an integrative predictive algorithm that incorporates multi-parameter inputs.

    Time frame: After all data are analyzed, up to approximately 60 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2023 (actual). Primary completion is estimated for Dec 2026, 47 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2023
First posted
Jun 23, 2023
StartActual
Jan 13, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2029
Last update
Jun 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05916755
Lead sponsor
Vall d'Hebron Institute of Oncology
Responsible party
Sponsor
First posted
Jun 23, 2023
Start date
Jan 13, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2029 (estimated)
Last update
Jun 23, 2023

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion